Advanced

Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort

Kim, Min ; Ali, Ashfaq LU and Legido-Quigley, Cristina (2019) In Alzheimer's and Dementia 15(6). p.817-827
Abstract
Introduction: A critical and as-yet unmet need in Alzheimer's disease (AD) is the discovery of peripheral small molecule biomarkers. Given that brain pathology precedes clinical symptom onset, we set out to test whether metabolites in blood associated with pathology as indexed by cerebrospinal fluid (CSF) AD biomarkers. Methods: This study analyzed 593 plasma samples selected from the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery study, of individuals who were cognitively healthy (n = 242), had mild cognitive impairment (n = 236), or had AD-type dementia (n = 115). Logistic regressions were carried out between plasma metabolites (n = 883) and CSF markers, magnetic resonance imaging,... (More)
Introduction: A critical and as-yet unmet need in Alzheimer's disease (AD) is the discovery of peripheral small molecule biomarkers. Given that brain pathology precedes clinical symptom onset, we set out to test whether metabolites in blood associated with pathology as indexed by cerebrospinal fluid (CSF) AD biomarkers. Methods: This study analyzed 593 plasma samples selected from the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery study, of individuals who were cognitively healthy (n = 242), had mild cognitive impairment (n = 236), or had AD-type dementia (n = 115). Logistic regressions were carried out between plasma metabolites (n = 883) and CSF markers, magnetic resonance imaging, cognition, and clinical diagnosis. Results: Eight metabolites were associated with amyloid β and one with t-tau in CSF, these were primary fatty acid amides (PFAMs), lipokines, and amino acids. From these, PFAMs, glutamate, and aspartate also associated with hippocampal volume and memory. Discussion: PFAMs have been found increased and associated with amyloid β burden in CSF and clinical measures. © 2019 (Less)
Please use this url to cite or link to this publication:
author
; and
author collaboration
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Alzheimer's disease, Amyloid, Biomarkers, Brain volume measurements, Cognitive function measurements, CSF, Dementia, EMIF-AD, Metabolomics, Tau, amide, amino acid, amyloid beta protein, aspartic acid, biological marker, cholinesterase inhibitor, fatty acid, glutamic acid, oleamide, tau protein, aged, Alzheimer disease, Article, brain function, brain size, cognition, cohort analysis, controlled study, dementia, disease association, female, hippocampus, human, logistic regression analysis, major clinical study, male, memory, metabolomics, mild cognitive impairment, Mini Mental State Examination, neuropsychological test, nuclear magnetic resonance imaging, plasma, predictive value, priority journal, protein cerebrospinal fluid level
in
Alzheimer's and Dementia
volume
15
issue
6
pages
11 pages
publisher
Wiley
external identifiers
  • scopus:85066602218
  • pmid:31078433
ISSN
1552-5279
DOI
10.1016/j.jalz.2019.03.004
language
English
LU publication?
no
id
99d3110d-e8e5-4fda-8176-29817b53074f
date added to LUP
2020-03-31 12:05:44
date last changed
2020-12-29 03:29:12
@article{99d3110d-e8e5-4fda-8176-29817b53074f,
  abstract     = {Introduction: A critical and as-yet unmet need in Alzheimer's disease (AD) is the discovery of peripheral small molecule biomarkers. Given that brain pathology precedes clinical symptom onset, we set out to test whether metabolites in blood associated with pathology as indexed by cerebrospinal fluid (CSF) AD biomarkers. Methods: This study analyzed 593 plasma samples selected from the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery study, of individuals who were cognitively healthy (n = 242), had mild cognitive impairment (n = 236), or had AD-type dementia (n = 115). Logistic regressions were carried out between plasma metabolites (n = 883) and CSF markers, magnetic resonance imaging, cognition, and clinical diagnosis. Results: Eight metabolites were associated with amyloid β and one with t-tau in CSF, these were primary fatty acid amides (PFAMs), lipokines, and amino acids. From these, PFAMs, glutamate, and aspartate also associated with hippocampal volume and memory. Discussion: PFAMs have been found increased and associated with amyloid β burden in CSF and clinical measures. © 2019},
  author       = {Kim, Min and Ali, Ashfaq and Legido-Quigley, Cristina},
  issn         = {1552-5279},
  language     = {eng},
  number       = {6},
  pages        = {817--827},
  publisher    = {Wiley},
  series       = {Alzheimer's and Dementia},
  title        = {Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort},
  url          = {http://dx.doi.org/10.1016/j.jalz.2019.03.004},
  doi          = {10.1016/j.jalz.2019.03.004},
  volume       = {15},
  year         = {2019},
}